欧州のリキッドバイオプシー市場：エンドユーザー別、国別 - 分析と予測（2024年～2033年）

欧州のリキッドバイオプシーの市場規模は、2024年に12億4,000万米ドルとなりました。

同市場は、2033年には55億8,000万米ドルに達すると予測され、予測期間の2024年～2033年のCAGRは18.18%と堅調な伸びを示すとみられています。欧州では、リキッドバイオプシーは新しい非侵襲的診断技術であり、がんの発見と監視に変革をもたらしつつあります。この方法は、がんの再発を早期に発見したり、治療効果を評価したりする可能性があり、最小限の侵襲でリアルタイムのモニタリングが可能です。がんの有病率の増加、研究論文の増加、臨床試験は、リキッドバイオプシー市場の成長を促進する要因の一部です。これらの要因がリキッドバイオプシー検査や製品に対する高い需要を生み出しています。低侵襲のがん検出法への嗜好の高まりの結果、より革新的で効率的な検査がより迅速に開発されています。

市場の成長はまた、がんの発見と治療管理の改善を目的とした政府の取り組みによっても大いに助けられています。リキッドバイオプシー製品は、オンラインプラットフォームや小売店など様々な流通経路を通じて広く入手可能であるため、欧州全域の消費者へのアクセスが向上し、より幅広いリーチが確保されています。これらの複合的要因が、欧州のリキッドバイオプシー市場の大きな牽引力となり、より効率的で利用しやすいがん検出ソリューションへの移行を支えています。

欧州のリキッドバイオプシー市場は、がんのモニタリングと発見に革命をもたらす非侵襲的診断技術として大きく拡大しています。リキッドバイオプシーは、血液サンプルから循環腫瘍DNA（ctDNA）、RNA、エクソソームを調べるもので、従来の生検技術に代わる強力な検査法です。リキッドバイオプシーは、リアルタイムのモニタリング、早期のがん再発の特定、治療効果の評価が可能であることから、がん領域での利用に拍車がかかっています。

欧州全体におけるがんの罹患率の増加、低侵襲診断技術に対する需要の高まり、研究と臨床試験の継続的な改善は、この市場の成長を促進する要因の一部です。リキッドバイオプシー技術が進歩するにつれ、個別化医療戦略をサポートし、より治療可能な段階でのがんの早期発見を可能にします。さらに、リキッドバイオプシーの応用範囲は、循環器科、神経科、感染症など、腫瘍学以外にも広がっています。

最先端技術の採用を促進し、がん診断を強化することを目的とした政府プログラムおよび規制当局の支援も、欧州市場を牽引しています。市場拡大をさらに後押ししているのは、学界、ヘルスケアプロバイダー、業界リーダー間のパートナーシップと研究資金の増加です。小売店やインターネットプラットフォームなどの流通経路の拡大により、リキッドバイオプシー製品は欧州全域の患者やヘルスケアプロバイダーに広く利用されるようになっています。

当レポートでは、欧州のリキッドバイオプシー市場について調査し、市場の概要とともに、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

• 市場動向
• サプライチェーン分析：欧州のリキッドバイオプシー市場
• 規制の枠組み
• COVID-19欧州のリキッドバイオプシー市場への影響
• 最近発売された製品/サービス
• 償還シナリオ
• 資金調達シナリオ
• 製品マッピング分析
• 総市場規模と浸透率
• 欧州のリキッドバイオプシー市場：ステークホルダー分析（N=30）
• リキッドバイオプシーに関する政府の取り組み
• 市場力学の概要

第2章 地域

• 欧州

第3章 市場-競合ベンチマーキングと企業プロファイル

• 企業プロファイル
  • Dxcover Limited
  • F. Hoffmann-La Roche Ltd.
  • GENinCode PLC (Abcodia Ltd.)
  • QIAGEN N.V.

第4章 調査手法

List of Figures

• Figure 1: Europe Liquid Biopsy Market, $Million, 2024, 2028, and 2033
• Figure 2: Liquid Biopsy Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3: Key Events to Keep Track of in the Liquid Biopsy Market
• Figure 4: Impact of COVID-19 on Liquid Biopsy Market
• Figure 5: Patent Published (by Country), January 2021-May 2024
• Figure 6: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
• Figure 7: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
• Figure 8: Europe Liquid Biopsy Market Scenario, 2023
• Figure 9: Frequently Used Technology in Liquid Biopsy
• Figure 10: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
• Figure 11: Treatment Guidelines for Treatment of Cancer Patients
• Figure 12: Major Challenges Faced While Performing Liquid Biopsy
• Figure 13: Average Cost of Technologies for the Europe Liquid Biopsy Market (N=30 )
• Figure 14: Cost Difference Across Different End Users for the Europe Liquid Biopsy Market
• Figure 15: Key Factors for Determining Reimbursement Possibility for the Europe Liquid Biopsy Market
• Figure 16: Estimated Global Cancer Incidence in 2020 and 2040
• Figure 17: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
• Figure 18: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
• Figure 19: Comparison of Liquid Biopsy vs. Tissue Biopsy
• Figure 20: Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 21: Europe Liquid Biopsy Market, $Million, 2023-2033
• Figure 22: Germany Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 23: Germany Liquid Biopsy Market, $Million, 2023-2033
• Figure 24: U.K. Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 25: U.K. Liquid Biopsy Market, $Million, 2023-2033
• Figure 26: France Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 27: France Liquid Biopsy Market, $Million, 2023-2033
• Figure 28: Italy Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 29: Italy Liquid Biopsy Market, $Million, 2023-2033
• Figure 30: Spain Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 31: Spain Liquid Biopsy Market, $Million, 2023-2033
• Figure 32: Rest-of-Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 33: Data Triangulation
• Figure 34: Top-Down and Bottom-Up Approach
• Figure 35: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Liquid Biopsy Market, Market Opportunities
• Table 3: Product Launches, January 2021-April 2024
• Table 4: Some of the Strategic Funding, January 2022-April 2024
• Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
• Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
• Table 7: Europe Liquid Biopsy Market: Key Players Patent Portfolio
• Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
• Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
• Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
• Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
• Table 12: Government Initiatives for Liquid Biopsies
• Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
• Table 15: Europe Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 16: Germany Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 17: U.K. Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 18: France Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 19: Italy Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 20: Spain Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 21: Rest-of-Europe Liquid Biopsy Market, $Million, 2023-2033
• Table 22: Rest-of-Europe Liquid Biopsy Market (by End User), $Million, 2023-2033

Introduction to Europe Liquid Biopsy Market

The Europe liquid biopsy market, valued at $1.24 billion in 2024, is expected to reach $5.58 billion by 2033, exhibiting a robust CAGR of 18.18% during the forecast period 2024-2033. In Europe, liquid biopsy is a new non-invasive diagnostic technique that is transforming cancer detection and surveillance. This method has the potential to early detect cancer recurrence or evaluate treatment responses, and it provides real-time monitoring with minimal invasiveness. The growing prevalence of cancer, rising research publications, and clinical trials are some of the factors driving the growth of the liquid biopsy market. These factors are creating higher demand for liquid biopsy tests and products. More innovative and efficient tests have been developed more quickly as a result of the growing preference for minimally invasive cancer detection methods.

The market's growth has also been greatly aided by government initiatives aimed at improving cancer detection and treatment management. Because liquid biopsy products are widely accessible through a variety of distribution channels, such as online platforms and retail stores, is enhancing accessibility and ensuring a broader reach to consumers across Europe. These combined factors are helping the liquid biopsy market in Europe gain significant traction, supporting the transition to more efficient and accessible cancer detection solutions.

Market Introduction

The market for liquid biopsies in Europe is expanding significantly as a non-invasive diagnostic technique that is revolutionizing cancer monitoring and detection. A potent substitute for conventional biopsy techniques, liquid biopsy examines blood samples for circulating tumor DNA (ctDNA), RNA, and exosomes. Its use in oncology is being fueled by its capacity to offer real-time monitoring, identify early cancer recurrence, and evaluate the effectiveness of treatment.

The growing incidence of cancer throughout Europe, the growing demand for minimally invasive diagnostic techniques, and continuous improvements in research and clinical trials are some of the factors driving this market's growth. As liquid biopsy technology advances, it supports personalized medicine strategies and allows early cancer detection at more treatable stages. Furthermore, the expansion of liquid biopsy applications extends beyond oncology, including uses in cardiology, neurology, and infectious diseases.

Government programs and regulatory assistance aimed at advancing the adoption of cutting-edge technologies and enhancing cancer diagnostics are also driving the European market. Further propelling market expansion are partnerships between academia, healthcare providers, and industry leaders, as well as increased research funding. The expansion of distribution channels, such as retail stores and internet platforms, is making liquid biopsy products more widely available to patients and healthcare providers throughout Europe.

Market Segmentation:

Segmentation 1: by End User

• Academic and Research Institutions
• Clinical Laboratories
• Pharmaceutical and Biotechnology
• Companies
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe liquid biopsy market has been segmented based on various categories, such as end user and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Dxcover Limited
• F. Hoffmann-La Roche Ltd.
• GENinCode Plc (Abcodia Ltd.)
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Trends
  • 1.1.1 Increasing Product Launches in the Market
  • 1.1.2 Growing Funding by the Key Players in the Market
• 1.2 Supply Chain Analysis: Europe Liquid Biopsy Market
• 1.3 Regulatory Framework
  • 1.3.1 Regulatory Framework in the European Union (EU)
  • 1.3.2 Regulation in Other Countries
• 1.4 COVID-19 Impact on Europe Liquid Biopsy Market
• 1.5 Recently Launched Product/Services
• 1.6 Reimbursement Scenario
• 1.7 Financing Scenario
  • 1.7.1 Key Players Patent Portfolio
  • 1.7.2 Key Players Stratification as per Raised Financing Value
  • 1.7.3 Key Players Financing Analysis (by Company)
• 1.8 Product Mapping Analysis
  • 1.8.1 By Technology
  • 1.8.2 By Sample
  • 1.8.3 By Circulating Biomarker
  • 1.8.4 By Clinical Application
• 1.9 Total Addressable Market and Penetration
• 1.1 Europe Liquid Biopsy Market: Stakeholder Analysis (N=30)
  • 1.10.1 Physicians' Perception
  • 1.10.2 Payer's Perception
  • 1.10.3 Investors' Perception
• 1.11 Liquid Biopsy Government Initiatives
• 1.12 Market Dynamics Overview
  • 1.12.1 Market Drivers
    • 1.12.1.1 Rising Burden of Cancer
    • 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
    • 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
  • 1.12.2 Market Restraints
    • 1.12.2.1 Technical Limitations in Liquid Biopsy
    • 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
  • 1.12.3 Market Opportunities
    • 1.12.3.1 Integration of AI in Liquid Biopsy
    • 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology

2 Regions

• 2.1 Europe
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Test Volume
  • 2.1.5 Market Size and Forecast
    • 2.1.5.1 By End User
  • 2.1.6 Germany
    • 2.1.6.1 Test Volume
    • 2.1.6.2 Market Size and Forecast
      • 2.1.6.2.1 By End User
  • 2.1.7 U.K.
    • 2.1.7.1 Test Volume
    • 2.1.7.2 Market Size and Forecast
      • 2.1.7.2.1 End User
  • 2.1.8 France
    • 2.1.8.1 Test Volume
    • 2.1.8.2 Market Size and Forecast
      • 2.1.8.2.1 By End User
  • 2.1.9 Italy
    • 2.1.9.1 Test Volume
    • 2.1.9.2 Market Size and Forecast
      • 2.1.9.2.1 By End User
  • 2.1.10 Spain
    • 2.1.10.1 Test Volume
    • 2.1.10.2 Market Size and Forecast
      • 2.1.10.2.1 By End User
  • 2.1.11 Rest-of-Europe
    • 2.1.11.1 Test Volume
    • 2.1.11.2 Market Size and Forecast
      • 2.1.11.2.1 By End User

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Dxcover Limited
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View
  • 3.1.2 F. Hoffmann-La Roche Ltd.
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Key Personnel
    • 3.1.2.5 Analyst View
  • 3.1.3 GENinCode PLC (Abcodia Ltd.)
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Key Personnel
    • 3.1.3.5 Analyst View
  • 3.1.4 QIAGEN N.V.
    • 3.1.4.1 Overview
    • 3.1.4.2 Top Products
    • 3.1.4.3 Top Competitors
    • 3.1.4.4 Key Personnel
    • 3.1.4.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast